In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.
The susceptibilities of 13 clinical isolates of Scedosporium apiospermum and 55 clinical isolates of S. prolificans to new and conventional drugs belonging to three different classes of antifungal agents, the azoles (miconazole, itraconazole, voriconazole, UR-9825, posaconazole), the polyenes (amphotericin B, nystatin and liposomal nystatin), and allylamines (terbinafine), were studied by use of proposed standard M38-P of NCCLS. Low growth-inhibitory antifungal activities were found in vitro for most of the drugs tested against S. prolificans isolates, with the MICs at which 90% of isolates are inhibited (MIC(90)s) being >8 microg/ml; the MIC(90)s of voriconazole and UR-9825, however, were 4 microg/ml. S. apiospermum isolates were more susceptible in vitro, with the highest activity exhibited by voriconazole (MIC(90)s, 0.5 microg/ml), followed by miconazole (MIC(90)s, 1 microg/ml), UR-9825 and posaconazole (MIC(90)s, 2 microg/ml), and itraconazole (MIC(90)s, 4 microg/ml). The MICs of terbinafine, amphotericin B, and the two formulations of nystatin (for which no statistically significant differences in antifungal activities were found for the two species) for S. apiospermum isolates were high. Cross-resistance was observed among all the azoles except posaconazole and among all the polyenes except the lipid formulation. A distribution analysis was performed with the MICs of each drug and for each species. Bimodal and skewed MIC distributions were obtained, and cutoffs indicating the borders of different MIC subpopulations of the distributions were determined on the basis of the normal plot technique. These cutoffs were in many cases reproducible between 48 and 72 h.
Meletiadis
Joseph
J
Departments of Medical Microbiology, University Medical Center, Nijmegen, The Netherlands.
Meis
Jacques F G M
JF
Mouton
Johan W
JW
Rodriquez-Tudela
Juan Luis
JL
Donnelly
J Peter
JP
Verweij
Paul E
PE
D000935:Antifungal Agents / Q000494:pharmacology*; D006801:Humans; D008825:Miconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009761:Nystatin / Q000494:pharmacology; D021681:Scedosporium / Q000187:drug effects* / Q000302:isolation & purification
D000935:Antifungal Agents; D009761:Nystatin; D008825:Miconazole